Alibaba Agrees to $600 Million Settlement Over Alleged Illegal Drug Sales in U.S.

Chinese e-commerce giant Alibaba has agreed to pay $600 million to settle allegations by the United States government that it failed to prevent the sale and importation of illegal pharmaceuticals, controlled substances, regulated chemicals and pill-making equipment through its online marketplaces.

The settlement, announced by the U.S. Department of Justice (DOJ), resolves a years-long investigation into the company’s compliance practices between 2016 and 2024. Rather than pursuing criminal charges, federal prosecutors entered into a non-prosecution agreement with Alibaba and its U.S.-based payment processor, AUS Merchant Services, provided both companies accepted responsibility for compliance failures and agreed to strengthen oversight measures.

According to the Justice Department, Alibaba failed to prevent approximately 80,000 unlawful product sales involving pharmaceuticals, listed chemicals, counterfeit drug-manufacturing equipment and pill presses that were imported into the United States in violation of the Federal Food, Drug, and Cosmetic Act. Authorities estimate the transactions had a combined value of more than $200 million.

Investigators said some merchants exploited Alibaba’s messaging system to move conversations to third-party platforms, where illegal transactions could be arranged with less oversight. Prosecutors also stated that company employees had previously raised concerns that Alibaba’s compliance controls were inadequate to stop prohibited products from being sold on its platforms.

The investigation involved multiple U.S. agencies, including the Food and Drug Administration (FDA), Internal Revenue Service Criminal Investigation (IRS-CI) and other federal law enforcement bodies. Officials revealed that investigators conducted more than 40 undercover purchases of illegal pharmaceuticals and related equipment as part of the probe, gathering evidence that helped build the government’s case.

Under the agreement, Alibaba and AUS Merchant Services will collectively pay $600 million through forfeitures and financial penalties while implementing stricter compliance systems, enhanced monitoring of merchants and improved safeguards against illegal product listings. The companies also pledged to cooperate with future law enforcement investigations involving prohibited goods.

In a statement, Alibaba said the settlement reflects its cooperation with U.S. authorities and its commitment to improving marketplace safety. The company emphasized that it has already taken significant steps to strengthen its compliance program and prevent unlawful sales by third-party merchants operating on its platforms.

U.S. officials described the case as one of the largest enforcement actions involving an international e-commerce marketplace. They said the resolution sends a strong message that online platforms and payment processors are expected to actively prevent the distribution of illegal pharmaceuticals and dangerous products, particularly when serving U.S. consumers.

While the settlement closes the federal investigation without criminal prosecution, it places Alibaba under heightened regulatory scrutiny and is expected to influence how global e-commerce companies monitor third-party sellers, particularly in markets where counterfeit medicines and controlled substances remain a growing concern.